BSX
Boston Scientific CorporationNYSEHealthcare$62.82+1.32%OpenMarket Cap: $93.22B
As of 2026-04-06
Valuation
P/E (TTM)
32.26
PEG
0.58
P/B
3.84
P/S
4.64
EV/EBITDA
21.11
DCF Value
$78.78
FCF Yield
3.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.0%
Operating Margin
19.8%
Net Margin
14.4%
ROE
12.5%
ROA
15.7%
ROIC
8.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $5.29B | 74.5% | $1.21B | $668.0M | $0.45 | — |
| FY 2025 | $20.07B | 69.0% | $3.97B | $2.89B | $1.94 | — |
| Q3 2025 | $5.07B | 69.9% | $1.05B | $755.0M | $0.50 | — |
| Q2 2025 | $5.06B | 67.7% | $819.0M | $793.0M | $0.53 | — |
| Q1 2025 | $4.66B | 63.3% | $896.0M | $674.0M | $0.45 | — |
| Q4 2024 | $4.56B | 58.6% | $589.0M | $566.0M | $0.38 | — |
| FY 2024 | $16.75B | 61.3% | $2.63B | $1.85B | $1.25 | — |
| Q3 2024 | $4.21B | 62.9% | $674.0M | $469.0M | $0.32 | — |
| Q2 2024 | $4.12B | 62.7% | $747.0M | $324.0M | $0.22 | — |
| Q1 2024 | $3.86B | 61.8% | $644.0M | $494.0M | $0.33 | — |
| Q4 2023 | $3.73B | 62.1% | $558.0M | $504.0M | $0.34 | — |
| FY 2023 | $14.24B | 62.0% | $2.18B | $1.59B | $1.07 | — |